Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GBM vs NRXS, FBIO, PYPD: FCF Margin % Comparison
For the Biotechnology subindustry, Inovio Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inovio Pharmaceuticals FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Inovio Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inovio Pharmaceuticals (FRA:GBM) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Inovio Pharmaceuticals and its competitors. According to the industry distribution chart, Inovio Pharmaceuticals ranks #937 out of 950 companies in the Biotechnology industry, placing it in the top 98.6%.
Is Inovio Pharmaceuticals' FCF Margin % too high?
Inovio Pharmaceuticals' current FCF Margin % is 0.00%. Based on the distribution chart, Inovio Pharmaceuticals ranks #937 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Inovio Pharmaceuticals has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inovio Pharmaceuticals' FCF Margin % compare to NRXS and FBIO?
According to the Biotechnology industry distribution chart, Inovio Pharmaceuticals ranks #937 out of 950 companies for FCF Margin %. This places Inovio Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Inovio Pharmaceuticals and its competitors. Inovio Pharmaceuticals's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inovio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Inovio Pharmaceuticals (FRA:GBM) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.19, compared to a current price of €1.02 — trading 434.2% above its estimated fair value. The current FCF Margin % is 0.00%. Inovio Pharmaceuticals' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Inovio Pharmaceuticals (FRA:GBM), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inovio Pharmaceuticals (FRA:GBM) Overvalued in 2026?
Based on GuruFocus' analysis, Inovio Pharmaceuticals stock appears to be overvalued.
The current stock price of €1.02 is trading 434.2% above its estimated GF Value™ of €0.19.
GuruFocus considers Inovio Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:GBM:
FCF Margin %: 0.00%
GF Value™: €0.19 vs. price of €1.02 (434.2% above fair value)
No single metric tells the full story. See the FRA:GBM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
43GF Score
Get the complete analysis for FRA:GBM
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GBM has been successfully added to your 
